Lead Candidate Selection Clause Samples
Lead Candidate Selection. Aktis shall provide a written report to the JRC when it in good faith believes that a Licensed Compound has achieved the applicable Lead Candidate Criteria. Thereafter, Aktis shall provide promptly to the JRC all data and information in Aktis’ possession and control in support thereof that is [***] for the JRC to confirm that such Licensed Compound has achieved the applicable Lead Candidate Criteria. Aktis shall provide promptly to the JRC any supplementary data or information in Aktis’ possession and control as may be requested by either of the JRC Co-Chairs. The JRC shall [***] discuss and evaluate such report and such data and information to determine whether or not the Licensed Compound has achieved the applicable Lead Candidate Criteria. In the event that the JRC determines that a Licensed Compound has achieved the Lead Candidate Criteria, then (a) such event shall be recorded in the minutes of the JRC, (b) such Licensed Compound shall be deemed a Lead Candidate and (c) ▇▇▇▇▇ shall pay the Research Collaboration Milestone Payment corresponding to the Lead Candidate Milestone in accordance with Section 8.3.1.
Lead Candidate Selection. Within fifteen (15) business days after the earliest to occur of the following events, Ohm shall pay to Aptose a one-time, non-refundable, non-creditable payment of [Redacted for confidentiality reasons.]: (a) the Advisory Committee’s designation (or deemed designation) of a Licensed Compound as a Lead Candidate pursuant to Section 4.2(b) and (b) Ohm’s commencement of IND-enabling toxicology studies with any Licensed Compound in compliance with GLP.
Lead Candidate Selection. On a Collaboration Program-by-Collaboration Program basis, the JRC will evaluate all relevant data generated in the Research Activities (including any generated by Amgen) and determine (by mutual agreement of both Parties in accordance with Section 3.1.5) whether any Collaboration Proteins have met the “Lead Candidate Criteria” and are thereafter deemed “Lead Candidates”; provided, however, that, unless otherwise agreed by the Parties, the number of Lead Candidates per Collaboration Target shall be capped at [***]. For each Collaboration Program, the earlier date upon which the (a) JRC determines the Lead Candidate Criteria has been achieved by at least one (1) Collaboration Protein or (b) Amgen initiates GLP Toxicology Studies with respect to any Collaboration Protein will be the “Lead Candidate Selection Date.” On a Collaboration Program-by-Collaboration Program basis, if by the end of the Research Term, the Lead Candidate Selection Date has not occurred, unless the JRC agrees otherwise, Generate’s obligations with respect to activities under the Collaboration Program will be considered completed; provided, Amgen may elect to continue directly or through its Affiliates or Subcontractors, the conduct of Research Activities with respect to such Collaboration Program. For clarity, irrespective of any JRC determination, if Amgen [***], the Lead Candidate Criteria will be deemed to have been met for such affected Collaboration Program and Collaboration Target.